Abstract
The authors discuss the impact of the recently available ‘atypical’ antipsychotic drugs on the management of people with schizophrenia. The better tolerability of the atypical agents, compared with conventional antipsychotics, should encourage their use as first-line therapy and therefore increase the acceptability of early intervention strategies. Tailoring treatment to the individual by appropriate selection of an atypical agent should facilitate the establishment of a productive, long-term therapeutic alliance and could achieve greater concordance between doctors and patients. Atypical antipsychotic drugs enable an improvement in management strategies which should contribute to a better outcome for patients with schizophrenia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Psychiatry in Clinical Practice
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
